Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by National University Hospital, Singapore.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT00716209
First received: July 14, 2008
Last updated: July 15, 2008
Last verified: July 2008
  Purpose

The proposal seeks to establish:

  • A comprehensive compilation (database) of clinical information comprising clinical, histopathological, treatment and follow-up characteristics of past and future gastrointestinal cancer (GIC) cases in Singapore that can be shared by investigators. The characteristics will include clinical (eg age, sex, stage), histopathological (eg. grade, type), treatment (eg. treatment status, regimens) and outcome data (eg. survival, toxicity) from medical records.
  • A collection (bank) of corresponding frozen and fixed tissue, blood and processed samples (enriched blood mononuclear cells, protein, RNA, DNA, tissue arrays) in Singapore that can be shared by the investigators.
  • A gastrointestinal cancer co-operative group (GCCG) of clinicians and scientists researching prognostic and predictive markers in GIC, which will benefit from the multi-disciplinary knowledge, information and samples of its members.
  • To characterise genetic polymorphisms related to Gastrointestinal cancer chemotherapy treatment in controls (healthy volunteers)

Condition
Gastrointestinal Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers

Resource links provided by NLM:


Further study details as provided by National University Hospital, Singapore:

Groups/Cohorts
1
Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Criteria

Inclusion Criteria:

  • Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00716209

Contacts
Contact: Ross Andrew Soo, MBBS Ross_Soo@nuh.com.sg

Locations
Singapore
National University Hospital Recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS     65-6772-4624     Ross_Soo@nuh.com.sg    
Sub-Investigator: Salto-Tellez Manuel            
Sponsors and Collaborators
National University Hospital, Singapore
Investigators
Principal Investigator: Ross Andrew Soo, MBBS National University Hospital, Singapore
Principal Investigator: Alex Chang Johns Hopkins University
Principal Investigator: Chung Yip Chan Tan Tock Seng Hospital